Webinar | Women’s Nutrition: Nourishing Womanhood From Pregnancy To Menopause
11 September | 12 PM ET: Register Now
Webinar | Women’s Nutrition: Nourishing Womanhood From Pregnancy To Menopause
11 September | 12 PM ET: Register Now
Seventeen high-revenue small-molecule drugs were examined beyond simple patent expiry timelines. The review incorporated regulatory protections, competitor filings, and supply arrangements, factors that often surface late in the planning cycle
As healthcare budgets across Europe remain under pressure, 2026 marks an important turning point. Multiple high-cost medicines are scheduled to lose regulatory exclusivity, enabling future price competition and expanded patient
In 2025, 98 drugs across Europe will lose market exclusivity, opening multi-billion-euro opportunities for generic and biosimilar manufacturers. These expirations span oncology, immunology, neurology, infectious diseases, and veterinary medicine, setting
Novo Nordisk’s Canadian Patent CA 2601784 (Acylated GLP-1 Compounds), protecting Ozempic and Wegovy’s active ingredient, semaglutide, has lapsed. This event, linked to the non-payment of a maintenance fee, has drawn
Several high-value drug patents are expiring as early as February 2025, along with their data exclusivities. The list includes Farxiga, Mounjaro, and Ozempic, opening a window for generic developers to
With an average life expectancy of 3-5 years after diagnosis, Pulmonary fibrosis highlights an urgent need for innovative therapeutic interventions. That’s where medications like Ofev have emerged as a transformative
Trajenta, known for its effective glycemic control without weight gain, is a key player in the diabetes medication sector. This critical medication, known generically as Linagliptin, is on the brink
The European Patent Office (EPO) receives more than 2000 oppositions each year, directly impacting the future success and exclusivity of pharmaceutical products. Monitoring the outcomes of these oppositions is crucial
While numerous drugs for diabetes are available in the market, many come with undesirable side effects such as weight gain, hypoglycemia, and hypertension. However, a game-changing solution has been introduced
The arthritis treatment industry is characterized by its intense competitiveness, driving companies to invest significantly in research and development to secure leading arthritis drug patents. Consequently, the expiration of patents
More than 500 million people around the world are affected by diabetes, and this issue is intensified by a surging obesity crisis, particularly in wealthier nations. In such a crisis,
The fiercely competitive nature of the oncology industry makes the companies invest heavily in research and development to bring in top cancer-treating drug patents. Consequently, the expiration of patents for
Given the competitive nature of the pharmaceutical domain, the expiration of drug patents presents significant opportunities, particularly for companies specializing in generic medications. Pharmaceutical companies seeking to expand or diversify
The recent FDA controversy around Novo Nordisk’s Ozempic has brought many eyes to the drug. For the uninitiated, Ozempic (semaglutide) is an anti-obesity medication for long-term weight management. However, an
Closely monitoring the patent expirations of well-known branded drugs, such as Abilify for schizophrenia and Abaraxane for cancer treatment, is essential. This practice of monitoring patents can give generic drug
In 2020, the FDA approved loteprednol etabonate ophthalmic suspension 0.25% (Eysuvis, Kala Pharmaceuticals Inc.) for treating dry eye disease. As one of the most common ocular surface disorders, dry eye
